You are here: Home > News Centre > Corporate News

Corporate News

CanSinoBio First Day Debut on the Main Board of SEHK Total Turnover of Approximately HK$820 million Closing Price Increased by 57.7% to HK$34.7


[28 March 2019, Hong Kong] CanSino Biologics Inc. (“CanSinoBio” or “Company”, stock code: 6185.HK), was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) and the dealing of its share commenced trading on 28 March 2019.


Shares were actively traded on the first trading day with excellent performance. Its share price closed at HK$34.7 with an intra-day high of HK$35.8 per share, representing an increase of 57.7% compared with the offer price of HK$22. A total of approximately 25,930,000 shares were traded, with an aggregate turnover of approximately HK$820 million.


Morgan Stanley Asia Limited and CLSA Capital Markets Limited are the Joint Sponsors. Morgan Stanley Asia Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators. Morgan Stanley Asia Limited, Morgan Stanley & Co. International plc, CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, ICBC International Capital Limited and CMB International Capital Limited are the Joint Bookrunners. Morgan Stanley Asia Limited, Morgan Stanley & Co. International plc, CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, ICBC International Securities Limited and CMB International Capital Limited are the Joint Lead Managers.


Founded in 2009, CanSinoBIO is committed to the development, production and commercialization of innovative vaccines, providing safer and more efficient vaccine products for public health and safety in China and globally while creating value for investors. China is the world's largest market for the potential demand of vaccine for human use, but China’s per capita spending on vaccines was only US$2.9 in 2017, which is less than 6% of the US. Vaccine product in China for human use has great potential in scale and quality. The scale of China’s vaccine market for human use is expected to reach RMB100.9 billion in 2030 at a CAGR of 11.2% from 2017 to 2030, of which private vaccine market at a CAGR of 12.3% from 2017 to 2030, amounting for more than 90% in market share. CanSinoBIO’s comprehensive and robust vaccine pipeline aims to address the vast and underserved market. In this process, enterprises with core technologies, innovative product pipeline and international perspective will gain greater competitive advantage. CanSinoBIO began building its commercialization infrastructure with a primary focus on China’s private vaccine market.


CanSinoBIO has 15 vaccine candidates for 12 disease areas. Among them, the Company’s globally innovative vaccine Ad5-EBOV is the first approved Ebola virus vaccine in Asia for emergency use and national stockpile. As compared to competing products from multi-national companies, CanSinoBIO’s Ad5-EBOV has shown a better stability profile and does not require ultra-low temperature storage conditions. The company's two new meningococcal vaccines are nearing commercialization: CanSinoBIO’s NDA-filed MCV2 candidate is a potential China best-in-class bi-valent meningococcal vaccine. Another brand new four-valent combination vaccine MCV4 plans to submit a new drug registration application within this year.


The Company's founders and management operations team are veterans of the vaccine industry including world-class scientists with a track record of leading the development and commercialization of innovative vaccines at global pharmaceutical companies such as Sanofi Pasteur, AstraZeneca and Wyeth (now Pfizer), having extensive experiences in global vaccine development, manufacturing, quality control and commercial operations. Contributing by the sound scientific background, robust experiences and technical know-how of CanSinoBIO’s team, CanSinoBIO has developed four platform technologies including adenovirus based viral vector vaccine technology, conjugation technology, protein structure design and recombinant technology and formulation technology that cover key advanced technologies in vaccine development and commercilization.


Dr. Xuefeng Yu, Chairman and Co-founder of CanSino Biologics Inc., said on the listing ceremony, “CanSinoBIO is a team with an international perspective and a deep understanding of the needs of the Chinese public health segment Our technology and vaccine products are  competitive on an international scale. Over the past 10 years, we have been committed to develop innovative vaccines and maintain strong product pipeline. In the future, we will focus on bringing our vaccine products to the market. China will be our biggest market, but we will not only focus on China. We believe that Chinese vaccine companies can also stand out on the international stages in the future.”


1234.jpg

 
Dr. Xuefeng Yu, Chairman and Co-founder of CanSino Biologics Inc., together with other co-founders, senior management and guests of the Company

1234-1.jpg

 
Dr. Xuefeng Yu, Chairman and Co-founder of CanSino Biologics Inc. and Mr Lin Liang, The Shareholder Representative, hit the gong to announce the start of trading